- Founded: 2013
- CEO: Kent Murphy, PhD
- Size of Facility: 10,000
- Company Size: 15
- Funding Source: Investor Funded
- Development Stage: Pre-clinical
AXON Dx™ is developing instruments and reagents that allow rapid, minimally invasive analysis of the CTCs shed by the primary and metastatic tumors. With a simple blood draw, the researcher will be able to identify and count the CTCs in a patient’s sample.